Loading
NASDAQHealthcareBiotechnology
Latest quote
$0.4175
−$0.0018 · -0.43%
Estrella Immunopharma, Inc. is an early-stage biopharmaceutical enterprise focused on creating T-cell therapies for various blood cancers and solid tumors, with its primary activities centered in the United States. The company's lead investigational drugs include EB103, which is in preclinical development for diffuse large B-cell lymphoma, and EB104, intended for the treatment of both diffuse large B-cell lymphoma and acute lymphocytic leukemia. Estrella also maintains a collaborative agreement with Imugene Limited, working together to develop solid tumor therapies that integrate Imugene's CF33-CD19t product candidate with Estrella's EB103. The company is based in Emeryville, California.
Previous close
$0.4175
−$0.0018 · -0.43%
Pre-market
$0.35
−$0.0675 · -16.17%
Oct 9, 9:14 AM ET
Regular session · ET · Market data may be delayed.
Estrella Immunopharma, Inc. is an early-stage biopharmaceutical enterprise focused on creating T-cell therapies for various blood cancers and solid tumors, with its primary activities centered in the United States. The company's lead investigational drugs include EB103, which is in preclinical development for diffuse large B-cell lymphoma, and EB104, intended for the treatment of both diffuse large B-cell lymphoma and acute lymphocytic leukemia. Estrella also maintains a collaborative agreement with Imugene Limited, working together to develop solid tumor therapies that integrate Imugene's CF33-CD19t product candidate with Estrella's EB103. The company is based in Emeryville, California.
Day range
Current $0.4175
52-week range
Current $0.4175
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
25
Expensive
Sentiment
50
Mixed
Risk
73
High Risk
Momentum
21
Weakening
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Estrella Immunopharma, Inc. is an early-stage biopharmaceutical enterprise focused on creating T-cell therapies for various blood cancers and solid tumors, with its primary activities centered in the United States. The company's lead investigational drugs include EB103, which is in preclinical development for diffuse large B-cell lymphoma, and EB104, intended for the treatment of both diffuse large B-cell lymphoma and acute lymphocytic leukemia. Estrella also maintains a collaborative agreement with Imugene Limited, working together to develop solid tumor therapies that integrate Imugene's CF33-CD19t product candidate with Estrella's EB103. The company is based in Emeryville, California.
Day range
Current $0.4175
52-week range
Current $0.4175
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Research and development | 10.25M USD | 6.41M USD | 4.11M USD | 10.45M USD | 1.39M USD |
| Selling, general, and administrative | 2.81M USD | 2.44M USD | 3.2M USD | 663.19K USD | 296.25K USD |
| Operating expenses | 13.06M USD | 8.85M USD | 7.31M USD | 11.11M USD | 1.69M USD |
| Interest income | — | — | — | — | 1.43K USD |
| Operating income | −13.06M USD | −8.85M USD | −7.31M USD | −11.11M USD | −1.69M USD |
| Net income | −13.06M USD | −8.85M USD | −7.31M USD | −11.11M USD | −1.69M USD |
Company facts updated Oct 9, 2026.
Recent quarterly results
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI
Vanguard Extended Market ETFVXF
iShares Micro-Cap ETFIWCAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
